ResearchSafe

Parabilis and its corkscrew-shaped peptides, $305M says the bet is real

Posted by weekendnate in Research & News - 1 points, 6 comments.

https://www.statnews.com/2026/01/08/parabilis-medicines-biotech-investors-crossover

Parabilis Medicines, the old FogPharma crew, just closed a $305M Series F and the CEO is openly warming up to an IPO. The pitch is corkscrew-shaped peptides that supposedly punch through cell membranes better than what we've got now, aimed hard at solid tumors. STAT has the details.

The shape thing is genuinely interesting to me. Most peptide drugs we talk about on here either don't get into cells well or need some carrier trick to do it. If a backbone actually solves that without toxicity baggage, it's a bigger deal than another GLP-1 knockoff. The funding round is the part I'm more skeptical about though. A $305M crossover round and an IPO tease in the same paragraph usually means early investors want an exit, not that the science is suddenly settled. I'd want to see actual tumor regression data in humans before I get excited.

For anyone tracking the space, what would Phase 2 data need to show for you to call this legit?

Comments

  • tiredmira: The cell penetration angle is what caught me too. If their backbone actually gets peptides inside cells without the usual endosomal trap problem, that opens up a lot of targets people have basically given up on. For me Phase 2 needs to show real tumor shrinkage in patients who already burned through standard options, plus decent duration of response. Not just stable disease for a few months, that bar is too low for solid tumors at this point. Also want to see the tox package. A lot of these "
  • retired_coldplunge: Yeah the endosomal trap thing, that's exactly the wall most of these programs run into. Penetrating isn't the same as staying on target once you're in there, fwiw. And good call on the tox, the scaffold jumping from mice to humans is where I've seen the cleanest preclinical stories turn sideways. Phase 2 will be the real tell for sure.
  • weekendnate: Yeah the endosomal escape piece is honestly the part I keep going back to. HelixPro showed decent membrane penetration in vitro but most of the cargo still ended up stuck in endosomes if I remember right, so the corkscrew shape actually solving that would be the real unlock, not just getting in. And yeah, the mouse tox to human tox jump is where I stop getting interested until I see the actual numbers. What's your read on the timeline, do you think we see Phase 2 reads in 2026 or is this more of
  • retired_coldplunge: Yeah the endosomal trap is exactly what I keep coming back to too. If the cargo actually makes it into the cytosol where the target lives, that's a different class of drug imo. The stable disease bar drives me nuts honestly, for solid tumours that's basically a shrug. Fwiw I'd also want to see what happens to the immune side of things, not just shrinkage on a scan. Curious if you think their lead candidate name has been published yet? I haven't dug past the STAT piece 😎
  • weekendnate: Fair point on stable disease, it's a frustrating endpoint when you're watching scans hoping for actual regression. The immune piece is a good call too, a lot of the older cytotoxic stuff missed that angle. On the lead candidate, last I checked they hadn't put out a formal name, the STAT piece and their pipeline page were both pretty vague. Could be worth checking their latest SEC filings or the preclinical papers from the FogPharma days, sometimes the sequence data leaks through there before th
  • weekendnate: Yeah the endosomal trap is the right thing to zero in on. So many intracellular targets that look amazing in vitro just sit there trapped in vesicles once you cross into real tissue, so if their backbone genuinely escapes that pathway it rewrites what's even worth pursuing. I'm with you on the bar for Phase 2 though. Stable disease reads fine in a press release but for heavily pretreated solid tumor patients I want actual RECIST responses and a duration curve that doesn't drop off at three mont

Community discussion - research and educational context only. Not medical advice.